AAAAAA

   
Results: 1-11 |
Results: 11
A STUDY OF MOLECULAR MARKERS WITH POTENTIAL PROGNOSTIC AND PREDICTIVEVALUE (C-ERBB-2, P53, CYCLIN D1, MIB1, ER AND PGR) IN LOCALLY ADVANCED BREAST-CANCER TREATED WITH NEOADJUVANT DOSE-INTENSIVE CHEMOTHERAPY IN AN EORTC-NCIC-SAKK RANDOMIZED PHASE-III STUDY
Authors: BONNEFOI H DIEBOLDBERGER S HAMILTON A VANDEVIJVER M MACGROGAN G SHEPHERD L AMARAL N RAOUST I DRIJKONINGEN M THERASSE P PICCART M
Citation: H. Bonnefoi et al., A STUDY OF MOLECULAR MARKERS WITH POTENTIAL PROGNOSTIC AND PREDICTIVEVALUE (C-ERBB-2, P53, CYCLIN D1, MIB1, ER AND PGR) IN LOCALLY ADVANCED BREAST-CANCER TREATED WITH NEOADJUVANT DOSE-INTENSIVE CHEMOTHERAPY IN AN EORTC-NCIC-SAKK RANDOMIZED PHASE-III STUDY, European journal of cancer, 34, 1998, pp. 133-133
CONTINUOUS INFUSIONAL 5-FLUOROURACIL (F) WITH EPIRUBICIN (E) AND CARBOPLATIN (ECARBOF) REGIMEN IN LOCALLY ADVANCED (LABC) OR METASTATIC BREAST-CANCER (MBC)
Authors: HUGLI A BONNEFOI H OBRIST R SAPPINO AP
Citation: A. Hugli et al., CONTINUOUS INFUSIONAL 5-FLUOROURACIL (F) WITH EPIRUBICIN (E) AND CARBOPLATIN (ECARBOF) REGIMEN IN LOCALLY ADVANCED (LABC) OR METASTATIC BREAST-CANCER (MBC), Annals of oncology, 9, 1998, pp. 89-89
EFFECT OF LOW-DOSE CHEST IRRADIATION BEFORE CHEMOTHERAPY ON THE RATE OF LOCAL FAILURE IN SMALL-CELL LUNG-CANCER
Authors: HOSLI P BONNEFOI H MIRIMANOFF RO MERMILLOD B ALBERTO P
Citation: P. Hosli et al., EFFECT OF LOW-DOSE CHEST IRRADIATION BEFORE CHEMOTHERAPY ON THE RATE OF LOCAL FAILURE IN SMALL-CELL LUNG-CANCER, International journal of radiation oncology, biology, physics, 41(2), 1998, pp. 287-289
ICON2 - RANDOMIZED TRIAL OF SINGLE-AGENT CARBOPLATIN AGAINST 3-DRUG COMBINATION OF CAP (CYCLOPHOSPHAMIDE, DOXORUBICIN, AND CISPLATIN) IN WOMEN WITH OVARIAN-CANCER
Authors: PARMAR MKB TORRI V BONAVENTURA A BONAZZI C COLOMBO N DELALOYE JF MARSONI S MANGIONI C SANDERCOCK J SESSA C WILLIAMS C TINAZZI A FLANN M GEISER K SCORPIGLIONE N STEWART JF CHAVES J PALMEIRO E CURTAIN A MCCORMACK T GENNATAS C MARRAS F OPPO TG BALESTRINO M MALZONI C MALZONI M BELLI M GEMINIANI ML CRESTANI G MONACO A VAVALA V PIATTO E BARATTINI G FORNARA PG CHETRI MC SANTEUFEMIA G ARTIOLI F CARONE D FANIZZA G TRENTADUE R PRIOLO D SCOLLO P NIGRO SC PETRINA M MASTRANTONIO P SPANNA GD ZAGNI R BELLONI C COLLEONI R REDAELLI L CAVAGNINI A DICOSTANZO G PERRONI D ARIENTI S ORFANOTTI G CANTONI FM SECLI R BIANCHI A MARTINELLO R MOLLICA G MAIZZI D PICCHIARELLI ME FIORINI G BORSANI M COLOMBO E GARSIA S MELGRATI L PAGGI G BRUNENGHI GM CASINI M ISA L ALGERI R PROZIO G BELFIORE G ANGELINI F DAPRILE M MORESCHI M MAURI ML NATALE N SENZANI FM PAVANATO G POGGI G GARUTI G LUERTI M CRUCIANI G PAGANO F BACCOLO M PODDI ER BOCCIOLONE L SABELLI MA MAGGI R RESTELLI C DANTONA A LOCATELLI MC PESSI A RAINA A CHIARI S GABRIELE A PITTELLI MR IACOBELLI P DOGLIOTTI L GORZEGNO G MUSSO P VEGNA G COCO G ALLETTI DG PICCIOTTO F LUCCHESE V EPIS A DIPALUMBO VS DRUDI G RAVAIOLI A ZAMPELLA D MORANDI MG GORGA G ZUCCHELLI C CARIELLO S GALLETTO L SUSSIO M MASSACESI L MASSACESI M CARLI A TUCCI E TAJANI E CORRADO G BUMMA S DURANDO A MASSOBRIO M SBERVEGLIERI M BIASIO M GUERCIO E JURA R DANESE S WIERDIS T FARNELLI C TARANTINO G GRASSI R REPETTI F ROCCHI B GRAMPA M ERCOLI A GRISO C SIGNORI E ZANINI L PRESTI M KLIMEK M URBANSKI K BISWAS A VIEGAS O KOCHLI O DREHER E FEY M BECK G LUDIN J BONNEFOI H KRAUER F BAUER J DELMORE G FURRER C LORENZ U THURLIMANN B LORENZ U BRONZ L SANNA P WYSS D GOLDHIRSCH A GYR T LEIDI L PASTORELLI G PAGANI O REY P HAILER U BENZ J KAYE SB REED NS SYMONDS RP ATKINSON RJ AXFORD AT RUSTIN G SECKL MJ GREEN JA SCOTT IV GUTHRIE D HARPER PG CALMAN F DOBBS HJ WEIR P CASSONI A LEDERMAN JA SOUHAMI RL BOZZINO J ADAB F REDMAN CWE SCOBLE JE PATERSON M DANIEL F COWLEY N WILLIAMS CJ SPOONER D HONG A MCILLMURRAY M HENDYIBBS P HALL V IVESON TJ WHITEHOUSE JMA GARRY R LAMONT A ROBINSON A TRASK CW CLUBB AW MURRELL D NEWMAN G WILKINS M GOLDTHORP WO ROBERTS JK RADSTONE DJ WHIPP MJ LEDERMANN JA PATER J BUYSE M OMURA G
Citation: Mkb. Parmar et al., ICON2 - RANDOMIZED TRIAL OF SINGLE-AGENT CARBOPLATIN AGAINST 3-DRUG COMBINATION OF CAP (CYCLOPHOSPHAMIDE, DOXORUBICIN, AND CISPLATIN) IN WOMEN WITH OVARIAN-CANCER, Lancet, 352(9140), 1998, pp. 1571-1576
SUBJECTIVE HEALTH ESTIMATIONS (SHE) IN PATIENTS WITH ADVANCED BREAST-CANCER - AN ADAPTED UTILITY CONCEPT FOR CLINICAL-TRIALS
Authors: HURNY C VANWEGBERG B BACCHI M BERNHARD J THURLIMANN B REAL O PEREY L BONNEFOI H COATES A
Citation: C. Hurny et al., SUBJECTIVE HEALTH ESTIMATIONS (SHE) IN PATIENTS WITH ADVANCED BREAST-CANCER - AN ADAPTED UTILITY CONCEPT FOR CLINICAL-TRIALS, British Journal of Cancer, 77(6), 1998, pp. 985-991
FORMESTANE VERSUS MEGESTROL-ACETATE IN POSTMENOPAUSAL BREAST-CANCER PATIENTS AFTER FAILURE OF TAMOXIFEN - A PHASE-III PROSPECTIVE RANDOMIZED CROSS-OVER TRIAL OF 2ND-LINE HORMONAL TREATMENT (SAKK-20 90)/
Authors: THURLIMANN B CASTIGLIONE M HSUSCHMITZ SF CAVALLI F BONNEFOI H FEY MF MORANT R LOHNERT T GOLDHIRSCH A
Citation: B. Thurlimann et al., FORMESTANE VERSUS MEGESTROL-ACETATE IN POSTMENOPAUSAL BREAST-CANCER PATIENTS AFTER FAILURE OF TAMOXIFEN - A PHASE-III PROSPECTIVE RANDOMIZED CROSS-OVER TRIAL OF 2ND-LINE HORMONAL TREATMENT (SAKK-20 90)/, European journal of cancer, 33(7), 1997, pp. 1017-1024
HOW SHOULD CANCER PRESENTING AS A MALIGNANT PLEURAL EFFUSION BE MANAGED
Authors: BONNEFOI H SMITH IE
Citation: H. Bonnefoi et Ie. Smith, HOW SHOULD CANCER PRESENTING AS A MALIGNANT PLEURAL EFFUSION BE MANAGED, British Journal of Cancer, 74(5), 1996, pp. 832-835
PHASE-II STUDY OF CONTINUOUS INFUSIONAL 5-FLUOROURACIL WITH EPIRUBICIN AND CARBOPLATIN (INSTEAD OF CISPLATIN) IN PATIENTS WITH METASTATIC LOCALLY ADVANCED BREAST-CANCER (INFUSIONAL ECARBOF) - A VERY ACTIVE ANDWELL-TOLERATED OUTPATIENT REGIMEN
Authors: BONNEFOI H SMITH IE OBRIEN MER SEYMOUR MT POWLES TJ ALLUM WH EBBS S BAUM M
Citation: H. Bonnefoi et al., PHASE-II STUDY OF CONTINUOUS INFUSIONAL 5-FLUOROURACIL WITH EPIRUBICIN AND CARBOPLATIN (INSTEAD OF CISPLATIN) IN PATIENTS WITH METASTATIC LOCALLY ADVANCED BREAST-CANCER (INFUSIONAL ECARBOF) - A VERY ACTIVE ANDWELL-TOLERATED OUTPATIENT REGIMEN, British Journal of Cancer, 73(3), 1996, pp. 391-396
INFUSIONAL 5-FLUOROURACIL (F) WITH EPIRUBICIN (E) AND CARBOPLATIN (ECARBOF) IN ADVANCED METASTATIC BREAST-CANCER (ABC) - CAN CARBO REPLACE CISPLATIN (C)
Authors: OBRIEN MER BONNEFOI H SEYMOUR M WALSH G RAMAGE F SMITH IE
Citation: Mer. Obrien et al., INFUSIONAL 5-FLUOROURACIL (F) WITH EPIRUBICIN (E) AND CARBOPLATIN (ECARBOF) IN ADVANCED METASTATIC BREAST-CANCER (ABC) - CAN CARBO REPLACE CISPLATIN (C), European journal of cancer, 31A, 1995, pp. 367-367
PRIMING LOW-DOSE CHEST RADIOTHERAPY FOLLOWED BY CHEMOTHERAPY FOR LIMITED SMALL-CELL LUNG-CANCER
Authors: BONNEFOI H ZULIAN GB MIRIMANOFF RO MERMILLOD B ALBERTO P
Citation: H. Bonnefoi et al., PRIMING LOW-DOSE CHEST RADIOTHERAPY FOLLOWED BY CHEMOTHERAPY FOR LIMITED SMALL-CELL LUNG-CANCER, Annals of oncology, 5(8), 1994, pp. 771-772
DOES PROPOFOL POSSESS ANTIDOPAMINERGIC PROPERTIES
Authors: BORGEAT A BONNEFOI H TRAMER M BISCHOFF P WILDERSMITH OHG RIFAT K
Citation: A. Borgeat et al., DOES PROPOFOL POSSESS ANTIDOPAMINERGIC PROPERTIES, Anesthesia and analgesia, 78(2), 1994, pp. 35-35
Risultati: 1-11 |